» Articles » PMID: 29378187

Apolipoprotein A-IV Enhances Cholecystokinnin Secretion

Overview
Journal Physiol Behav
Date 2018 Jan 30
PMID 29378187
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Cholecystokinin (CCK) and apolipoprotein A-IV (ApoA-IV) are gastrointestinal peptides that play an important role in controlling energy homeostasis. Lymphatic ApoA-IV and plasma CCK secretion are mediated via a chylomicron formation-dependent pathway during a dietary lipid infusion. Given their similar roles as satiating proteins, the present study examines how the two peptides interact in their function. Specifically, this study sought to understand how ApoA-IV regulates CCK secretion. For this purpose, Cck gene expression in the small intestines of ApoA-IV knockout (ApoA-IV-KO) and wild-type (WT) mice were compared under an array of feeding conditions. When fed with a chow or high-fat diet (HFD), basal levels of Cck transcripts were significantly reduced in the duodenum of ApoA-IV-KO mice compared to WT mice. Furthermore, after an oral gavage of a lipid mixture, Cck gene expression in the duodenum was significantly reduced in ApoA-IV-KO mice relative to the change seen in WT mice. To determine the mechanism by which ApoA-IV modulates Cck gene expression, STC-1 cells were transfected with predesigned mouse lysophosphatidic acid receptor 5 (LPAR5) small interfering RNA (siRNA) to knockdown Lpar5 gene expression. In this in-vitro study, mouse recombinant ApoA-IV protein increased Cck gene expression in enteroendocrine STC-1 cells and stimulated CCK release from the STC-1 cells. However, the levels of CCK protein and Cck expression were attenuated when Lpar5 was knocked down in the STC-1 cells. Together these observations suggest that dietary lipid-induced ApoA-IV is associated with Cck synthesis in the duodenum and that ApoA-IV protein directly enhances CCK release through the activation of a LPAR5-dependent pathway.

Citing Articles

Mechanism of Skin Peptides in Alleviating Hyperglycemia in Rats with Type 2 Diabetic Mellitus Based on Microbiome and Metabolome Analyses.

Xu M, Chen B, Qiao K, Liu S, Su Y, Cai S Mar Drugs. 2024; 22(8).

PMID: 39195493 PMC: 11355842. DOI: 10.3390/md22080377.

References
1.
Weinstock P, Bisgaier C, Hayek T, Aalto-Setala K, Sehayek E, Wu L . Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res. 1997; 38(9):1782-94. View

2.
Kotarsky K, Boketoft A, Bristulf J, Nilsson N, Norberg A, Hansson S . Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther. 2006; 318(2):619-28. DOI: 10.1124/jpet.105.098848. View

3.
Liddle R, Green G, Conrad C, Williams J . Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat. Am J Physiol. 1986; 251(2 Pt 1):G243-8. DOI: 10.1152/ajpgi.1986.251.2.G243. View

4.
Choi S, Lee M, Shiu A, Yo S, Hallden G, Aponte G . GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells. Am J Physiol Gastrointest Liver Physiol. 2007; 292(5):G1366-75. DOI: 10.1152/ajpgi.00516.2006. View

5.
Liddle R, Goldfine I, Rosen M, Taplitz R, Williams J . Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest. 1985; 75(4):1144-52. PMC: 425438. DOI: 10.1172/JCI111809. View